WO2019166782A1 - Catalysts - Google Patents

Catalysts Download PDF

Info

Publication number
WO2019166782A1
WO2019166782A1 PCT/GB2019/050489 GB2019050489W WO2019166782A1 WO 2019166782 A1 WO2019166782 A1 WO 2019166782A1 GB 2019050489 W GB2019050489 W GB 2019050489W WO 2019166782 A1 WO2019166782 A1 WO 2019166782A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
compound
halo
alkoxy
Prior art date
Application number
PCT/GB2019/050489
Other languages
French (fr)
Inventor
Dermot O'hare
Jean-Charles BUFFET
Zoe R. TURNER
Thomas Robinson
Original Assignee
Scg Chemicals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scg Chemicals Co., Ltd. filed Critical Scg Chemicals Co., Ltd.
Publication of WO2019166782A1 publication Critical patent/WO2019166782A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • B01J31/2282Unsaturated compounds used as ligands
    • B01J31/2295Cyclic compounds, e.g. cyclopentadienyls
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/78Preparation processes
    • C08G63/82Preparation processes characterised by the catalyst used
    • C08G63/823Preparation processes characterised by the catalyst used for the preparation of polylactones or polylactides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/10Polymerisation reactions involving at least dual use catalysts, e.g. for both oligomerisation and polymerisation
    • B01J2231/14Other (co) polymerisation, e.g. of lactides or epoxides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/40Complexes comprising metals of Group IV (IVA or IVB) as the central metal
    • B01J2531/46Titanium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/40Complexes comprising metals of Group IV (IVA or IVB) as the central metal
    • B01J2531/48Zirconium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/40Complexes comprising metals of Group IV (IVA or IVB) as the central metal
    • B01J2531/49Hafnium

Definitions

  • the present invention relates to new catalytic compounds. More specifically, the present invention relates to catalytic compounds suitable for use in the polymerisation of cyclic esters and/or cyclic amides.
  • PLAs Poly(lactic acids)
  • PLAs Poly(lactic acids)
  • PLAs are both biodegradable and biocompatible, they are of equal value to the field of medicine, wherein their versatile physical properties make them suitable for in vivo applications (e.g. as media for controlled drug delivery devices).
  • (m-nC) or "(m-nC) group” used alone or as a prefix, refers to any group having m to n carbon atoms.
  • alkyl refers to straight or branched chain alkyl moieties, typically having 1 , 2, 3, 4, 5 or 6 carbon atoms. This term includes reference to groups such as methyl, ethyl, propyl (n-propyl or isopropyl), butyl (n-butyl, sec-butyl or tert-butyl), pentyl, hexyl and the like. In particular, an alkyl may have 1 , 2, 3 or 4 carbon atoms.
  • alkenyl refers to straight or branched chain alkenyl moieties, typically having 1 , 2, 3, 4, 5 or 6 carbon atoms.
  • This term includes reference to groups such as ethenyl (vinyl), propenyl (allyl), butenyl, pentenyl and hexenyl, as well as both the cis and trans isomers thereof.
  • alkynyl refers to straight or branched chain alkynyl moieties, typically having 1 , 2, 3, 4, 5 or 6 carbon atoms.
  • the term includes reference to alkynyl moieties containing 1 , 2 or 3 carbon-carbon triple bonds (CoC). This term includes reference to groups such as ethynyl, propynyl, butynyl, pentynyl and hexynyl.
  • haloalkyl refers to alkyl groups being substituted with one or more halogens (e.g. F, Cl, Br or I). This term includes reference to groups such as 2-fluoropropyl, 3-chloropentyl, as well as perfluoroalkyl groups, such as perfluoromethyl.
  • alkoxy refers to -O-alkyl, wherein alkyl is straight or branched chain and comprises 1 , 2, 3, 4, 5 or 6 carbon atoms. In one class of embodiments, alkoxy has 1 , 2, 3 or 4 carbon atoms. This term includes reference to groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentoxy, hexoxy and the like.
  • aryl or“aromatic” as used herein means an aromatic ring system comprising 6, 7, 8, 9 or 10 ring carbon atoms.
  • Aryl is often phenyl but may be a polycyclic ring system, having two or more rings, at least one of which is aromatic. This term includes reference to groups such as phenyl, naphthyl and the like. Unless otherwise specification, aryl groups may be substituted by one or more substituents. A particularly suitable aryl group is phenyl.
  • aryloxy refers to -O-aryl, wherein aryl has any of the definitions discussed herein. Also encompassed by this term are aryloxy groups in having an alkylene chain situated between the O and aryl groups.
  • halogen or“halo” as used herein refers to F, Cl, Br or I. In a particular, halogen may be F or Cl, of which Cl is more common.
  • substituted as used herein in reference to a moiety means that one or more, especially up to 5, more especially 1 , 2 or 3, of the hydrogen atoms in said moiety are replaced independently of each other by the corresponding number of the described substituents.
  • optionally substituted as used herein means substituted or unsubstituted.
  • cyclic esters and“cyclic amides” as used herein refer to heterocycles containing at least one ester or amide moiety. It will be understood that lactides, lactones and lactams are encompassed by these terms.
  • the first aspect of the invention provides a compound having a structure according to formula (I) shown below:
  • X is selected from zirconium or hafnium; Y is selected from:
  • halo hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NR a R b , - NR a R b , aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, nitro, -NR a R b , aryl, (1- 6C)alkoxy, -C(0)NR a R b , and Si[(1-4C)alkyl] 3 , or
  • each R x is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1-3C)fluoroalkyl, aryl and aryloxy, and
  • R y is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1-3C)fluoroalkyl, aryl and aryloxy;
  • each R 1 is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1- 3C)fluoroalkyl, aryl and aryloxy; and
  • R 2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1- 3C)fluoroalkyl, aryl and aryloxy;
  • R a and R b are independently hydrogen or (1-4C)alkyl.
  • the new compounds which contain a permethylpentalene (“Pn*”) ligands and an amidinate ligand, are particularly active in the polymerisation of lactides and lactones (e.g. e-caprolactone).
  • the compound of formula (I) may exist as a dimer. It will be understood that such dimeric forms of the compound of formula (I) are within the scope of the present invention. Dimeric forms of the compound of formula (I) may adopt the general structure:
  • X is zirconium
  • X may also be titanium.
  • each R 1 group is independently selected from (1-6C)alkyl, (2- 4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1-3C)fluoroalkyl, aryl and aryloxy.
  • each R 1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
  • each R 1 group is independently selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1- 6C)alkoxy, aryl and aryloxy.
  • each R 1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
  • each R 1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with 1-3 groups selected from halo, (1-4C)alkyl and (1- 2C)alkoxy.
  • each R 1 group is independently selected from methyl, ethyl, isopropyl and tertbutyl, or each R 1 group is independently a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl.
  • Both R 1 groups are suitably identical to one another.
  • R 2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
  • R 2 is selected from hydrogen, (1-6C)alkyl, -N'Pr'Pr and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, (1- 3C)fluoroalkyl, aryl and aryloxy.
  • R 2 is selected from hydrogen, (1-4C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, aryl and aryloxy.
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1- 4C)alkyl.
  • R a and R b are independently selected from methyl, ethyl, iso-propyl and tert-butyl.
  • R a and R b are independently selected from methyl, ethyl and iso-propyl.
  • R a and R b are identical.
  • Y is i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NR a R b , -NR a R b , aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1- 4C)alkyl, nitro, -NR a R b , aryl, (1-6C)alkoxy, -C(0)NR a R b , and Si[(1-4C)alkyl] 3 , or iii) a ligand having a structure according to formula A, wherein each R x has any of the definitions discussed hereinbefore in relation to R 1 , and R y has any of the definitions discussed hereinbefore in relation to R 2 .
  • Y is
  • halo hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NR a R , -NR a R , aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1- 4C)alkyl, nitro, -NR a R b , aryl, (1-6C)alkoxy, -C(0)NR a R b , and Si[(1-4C)alkyl] 3 , or iii) a ligand having a structure according to formula A, wherein both R 1 groups are identical, each R x is identical to R 1 , and R y is identical to R 2 .
  • Y is
  • halo or ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, -NR a R b , aryl, (1- 6C)alkoxy, -C(0)NR a R , and Si[(1-4C)alkyl] 3 .
  • halo or ii) (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, aryl and (1-6C)alkoxy.
  • halo or ii) (1-4C)alkyl, (1-4C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
  • Y is
  • Y is
  • the compound of formula (I) has a structure according to formula (la) shown below:
  • X, Y and R 2 have any of the definitions discussed hereinbefore in respect of formula (I); each R 3 is independently selected from (1-4C)alkyl and (1-3C)fluoroalkyl; and each n is independently 0,1 , 2 or 3.
  • the compound of formula (I) has a structure according to formula (la), wherein
  • X, Y and R 2 have any of the definitions discussed hereinbefore in respect of formula (I);
  • each R 3 is independently an ortho or para substituent selected from (1-4C)alkyl and (1- 3C)fluoroalkyl;
  • each n is independently 0, 1 , 2 or 3.
  • the compound of formula (I) has a structure according to formula (la), wherein
  • X is zirconium
  • R 2 is selected from hydrogen, (1-6C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy
  • Y is: i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NR a R b , -NR a R b , aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1- 4C)alkyl, nitro, -NR a R b , aryl, (1-6C)alkoxy, -C(0)NR a R b , and Si[(1-4C)alkyl] 3 , or iii) an amidinate ligand identical to that depicted in formula (la) (i.e. that comprising groups R 1 and R 2 ); each R 3 is independently an ortho or para substituent selected from (1-4C)alkyl and (1- 3C)fluoroalkyl; and
  • each n is independently 0, 1 , 2 or 3.
  • the compound of formula (I) has a structure according to formula (la), wherein
  • X is zirconium
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl;
  • Y is: i) halo, or ii) (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, aryl and (1-6C)alkoxy; each R 3 is independently an ortho or para substituent selected from (1-4C)alkyl and (1- 3C)fluoroalkyl; and
  • each n is independently 0, 1 , 2 or 3.
  • the compound of formula (I) has a structure according to formula (la), wherein
  • X is zirconium
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl;
  • Y is: i) chloro, or ii) (1-4C)alkoxy or a phenoxy group that is optionally substituted with 1 or 2 (1-4C)alkyl groups; each R 3 is independently an ortho or para substituent selected from methyl, iso-propyl and trifluoromethyl; and
  • each n is independently 0, 1 , 2 or 3.
  • the compound of formula (I) has a structure according to formula (lb) shown below:
  • X, Y and R 2 have any of the definitions discussed hereinbefore in respect of formula (I).
  • the compound of formula (I) has a structure according to formula (lb), wherein X is zirconium;
  • R 2 is selected from hydrogen, (1-6C)alkyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, (1- 3C)fluoroalkyl, aryl and aryloxy;
  • Y is: i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NR a R b , -NR a R b , aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1- 4C)alkyl, nitro, -NR a R b , aryl, (1-6C)alkoxy, -C(0)NR a R b , and Si[(1-4C)alkyl] 3 , or iii) an amidinate ligand identical to that depicted in formula (la) (i.e. that comprising groups R 1 and R 2 ).
  • the compound of formula (I) has a structure according to formula (lb), wherein
  • X is zirconium
  • R 2 is selected from hydrogen, (1-4C)alkyl, -N'PHPr and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy and (1- 3C)fluoroalkyl;
  • Y is: i) halo, or ii) (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, aryl and (1-6C)alkoxy.
  • the compound of formula (I) has a structure according to formula (lb), wherein
  • X is zirconium
  • R 2 is selected from hydrogen, (1-4C)alkyl, -N'PHPr and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy and trifluoromethyl;
  • Y is: i) chloro, or ii) (1-4C)alkoxy or a phenoxy group that is optionally substituted with 1 or 2 (1-4C)alkyl groups.
  • the compound of formula (I) has a structure according to formula (lc) shown below:
  • X, R 1 and R 2 have any of the definitions discussed hereinbefore in respect of formula (I).
  • the compound of formula (I) has a structure according to formula (lc) wherein
  • X is zirconium
  • each R 1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy; and
  • R 2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
  • the compound of formula (I) has a structure according to formula (lc) wherein
  • X is zirconium
  • each R 1 group is independently selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, (1- 3C)haloalkyl, aryl and aryloxy; and R 2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -N'Pr'Pr and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
  • the compound of formula (I) has a structure according to formula (lc) wherein
  • X is zirconium
  • each R 1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy; and
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
  • the compound of formula (I) has a structure according to formula (lc) wherein
  • X is zirconium
  • R 1 group is selected from methyl, ethyl, isopropyl and tertbutyl, or R 1 group is a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl; and
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
  • the compound of formula (I) has a structure according to formula (Id) shown below:
  • R 4 is selected from (1-4C)alkyl and aryl, either or which is optionally substituted with one or more substituents selected from (1-4C)alkyl and (1-3C)fluoroalkyl.
  • the compound of formula (I) has a structure according to formula (Id) wherein
  • X is zirconium
  • each R 1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy;
  • R 2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy; and
  • R 4 is selected from (1-4C)alkyl and phenyl, either or which is optionally substituted with one or more substituents selected from (1-4C)alkyl and (1-3C)fluoroalkyl.
  • the compound of formula (I) has a structure according to formula (Id) wherein
  • X is zirconium
  • each R 1 group is independently selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, (1- 3C)haloalkyl, aryl and aryloxy; and
  • R 2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -N'Pr'Pr and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
  • the compound of formula (I) has a structure according to formula (Id) wherein
  • X is zirconium
  • each R 1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy;
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy; and R 4 is selected from methyl, iso-propyl, tert-butyl and phenyl, either or which is optionally substituted with one or more substituents selected from methyl, iso-propyl, tert-butyl and trifluoromethyl.
  • the compound of formula (I) has a structure according to formula (Id) wherein
  • X is zirconium
  • R 1 group is selected from methyl, ethyl, isopropyl and tertbutyl, or R 1 group is a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl;
  • R 2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl;
  • R 4 is selected from tert-butyl, 2,6-dimethyl phenyl and 2,6-diisopropyl phenyl.
  • the compound of formula (I) has any of the following structures:
  • the compound of formula (I) has any of the following structures:
  • the compound of formula (I) has any of the following structures:
  • the compound of formula (I) has any of the following structures:
  • the compound of formula (I) is immobilised on a solid support material. Supporting the compound on such a solid support allows the resulting material to be used in slurry phase (as opposed to solution phase) catalysis. Suitable solid support materials will be familiar to one of ordinary skill in the art.
  • the compound of formula (I) may be supported directly or indirectly (e.g. by a linking moiety) on the solid support material. It will be understood that the compound of formula (I) may undergo one or more minor structure modifications (e.g. loss of the group Y) as a consequence of having been immobilised on a solid support material. Such minor structural modifications are within the scope of the invention.
  • the compounds of formula (I) may be synthesised by any suitable process known in the art. Particular examples of processes for the preparation of the compounds are set out in the accompanying examples.
  • the compounds of formula (I) are prepared according to a process comprising the steps of:
  • X is as defined in formula (I)
  • M is a metal (such as Li, Na or K) and Q is halo (e.g. chloro);
  • R 1 and R 2 are as defined in formula (I) and M + is a metal cation (such as Li + , Na + or K + ); and optionally thereafter
  • Y is as defined in formula (I) and M is a metal (such as Li, Na or K).
  • step b) is typically implemented.
  • M is Li in step a).
  • Any suitable solvent may be used for steps a) and b) of the process defined above.
  • a particularly suitable solvent may be, for example, diethyl ether, toluene, THF, dichloromethane, chloroform, hexane DMF, benzene etc.
  • step a) the compound of formula (III) is typically added dropwise to the compound of formula (II) in order to prevent double ligand substitution (unless this is desired).
  • reaction conditions e.g. temperature, pressures, reaction times, agitation etc.
  • X is selected from zirconium, hafnium and titanium;
  • Y is selected from:
  • halo hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NR a R b , - NR a R b , aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, nitro, -NR a R b , aryl, (1- 6C)alkoxy, -C(0)NR a R b , and Si[(1-4C)alkyl] 3 , or
  • each R x is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1-3C)fluoroalkyl, aryl and aryloxy, and
  • R y is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1-3C)fluoroalkyl, aryl and aryloxy;
  • each R 1 is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1- 3C)fluoroalkyl, aryl and aryloxy; and R 2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a
  • R a and R b are independently hydrogen or (1-4C)alkyl.
  • the compound of statement 1 wherein X is zirconium.
  • each R 1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NR a R b , (1-6C)alkoxy, -C(0)NR a R b , (1-3C)fluoroalkyl, aryl and aryloxy.
  • each R 1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
  • each R 1 group is independently selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy.
  • each R 1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
  • each R 1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with 1-3 groups selected from halo, (1-4C)alkyl and (1-2C)alkoxy.
  • each R 1 group is independently selected from methyl, ethyl, isopropyl and tertbutyl, or each R 1 group is independently a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl.
  • R 1 groups are identical
  • R 2 is selected from hydrogen, (1- 6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NR a R b and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
  • R 2 is selected from hydrogen, (1- 6C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy.
  • R 2 is selected from hydrogen, (1- 4C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, aryl and aryloxy.
  • R 2 is selected from hydrogen, (1- 4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
  • R 2 is selected from hydrogen, (1- 4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
  • R 2 is selected from hydrogen, (1- 4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
  • the compound of any preceding statement, wherein the group -(R 1 )N-CH(R 2 )-N(R 1 )- is an amidinate ligand having any one of the following structures:
  • X, Y and R 2 are as defined in any preceding statement; each R 3 is independently selected from (1-4C)alkyl and (1-3C)fluoroalkyl; and each n is independently 0, 1 , 2 or 3.
  • R 4 is selected from (1-4C)alkyl and aryl, either or which is optionally substituted with one or more substituents selected from (1-4C)alkyl and (1-3C)fluoroalkyl.
  • the compound of statement 1 wherein the compound has any of the following structures:
  • Fig. 1 shows the 1 H NMR spectrum of Pn * Zr(CI)(HC(N-2,6-'Pr-C 6 H 3 ) 2 ) recorded at 298 K in CD2CI2. * denotes NMR solvent residue.
  • Fig. 2 shows the molecular structure of Pn * Zr(CI)(HC(N-2,6-'Pr-C 6 H 3 ) 2 ), shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity.
  • Fig. 3 shows the 1 H NMR spectrum of Pn * Zr(CI)(MeC(N'Pr)2) recorded at 298 K in Ob ⁇ d . * denotes NMR solvent residue.
  • Fig. 4 shows the molecular structure of dimeric [Pn * Zr(CI)(MeC(N'Pr)2)]2, shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity.
  • Fig. 5 shows the 1 H NMR spectrum of Pn * Zr(CI)(PhC(N'Pr)2) recorded at 298 K in Ob ⁇ d . * denotes NMR solvent residue and residual THF.
  • Fig. 6 shows the molecular structure of Pn * Zr(CI)(PhC(N'Pr)2), shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity.
  • An additional symmetry inequivalent molecule composes the asymmetric unit and is also omitted for clarity.
  • Fig. 7 shows the 1 H NMR spectrum of Pn * Zr(CI)(HC(N-4-Me-C6H4)2) recorded at 298 K in CD2CI2. *denotes NMR solvent residue and residual hexane.
  • Fig. 8 shows the molecular structure of dimeric [Pn * Zr(CI)(HC(N-4-Me-C 6 H 4 ) 2 )] 2 , shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity.
  • Fig. 9 shows the 1 H NMR spectrum of Pn * Zr(0-2,6-Me-C 6 H 3 )(PhC(N'Pr) 2 ) recorded at 298 K in O d ⁇ d . *denotes NMR solvent residue.
  • Fig. 10 shows the molecular structure of Pn * Zr(0-2,6-Me-C 6 H 3 )(PhC(N'Pr) 2 ), shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity.
  • An additional symmetry inequivalent molecule composes the asymmetric unit and is also omitted for clarity.
  • Fig. 11 is a plot showing conversion of L-lactide to Polylactide as a function of time using the compounds of Example 1. Reactions catalysed by the series of permethylpentalene zirconium catalysts. Polymerisations were performed in a 0.5M L-lactide solution in Ob ⁇ d at 80 °C with 2 mol% [Zr]
  • Fig. 12 is a plot showing concentration of e-caprolactone monomer as a function of polymerisation time using Pn * Zr(0-2,6-Me-C 6 H 3 )(PhC(N'Pr) 2 ), with the reaction following a zero order rate law. Polymerisations were performed in a 0.5M e-caprolactone solution in Ob ⁇ d at room temperature with 2 mol% Pn * Zr(0-2,6-Me-C6H 3 )(PhC(N'Pr) 2 ).
  • Fig. 13 shows the 1 H NMR spectrum of Pn*Zr ⁇ ('PrN) 2 C(4-OMe-C 6 H 4 ) ⁇ CI recorded at 298K in O d ⁇ d . *denotes NMR solvent residue and # denotes residual thf.
  • Fig. 14 shows the 1 H NMR spectrum of Pn*Zr ⁇ ('PrN) 2 C(4-CF 3 -C 6 H 4 ) ⁇ CI recorded at 298K in Ob ⁇ d . *denotes NMR solvent residue and # denotes residual thf.
  • Fig. 15 shows the 1 H NMR spectrum of Pn*Ti ⁇ (2,6-'PrC 6 H 3 N) 2 CH ⁇ CI recorded at 298K in Ob ⁇ d . *denotes NMR solvent residue.
  • Fig. 16 shows the 1 H NMR spectrum of Pn*Ti ⁇ ('PrN)2C(C6H5) ⁇ CI recorded at 298K in CeD 6 . *denotes NMR solvent residue and # denotes residual pentane.
  • [0084] [Pn*ZrCl2]2LiCI THF x (0.114 mmol) and a metal salt of the desired ligand (M-L*, 0.229 mmol) were combined as solids in a Schlenk tube and toluene (3 ml_) was added at room temperature.
  • Fig. 1 shows the 1 H NMR spectrum of Pn * Zr(CI)(HC(N-2,6-'Pr-C 6 H 3 ) 2 ) recorded at 298 K in CD2CI2.
  • the molecular structure is depicted in Fig. 2.
  • Fig. 3 shows the 1 H NMR spectrum of Pn * Zr(CI)(MeC(N'Pr)2) recorded at 298 K in CeD 6 .
  • the molecular dimeric structure is depicted in Fig. 4.
  • Fig. 5 shows the 1 H NMR spectrum of Pn * Zr(CI)(PhC(N'Pr)2) recorded at 298 K in CeD 6 .
  • the molecular structure is depicted in Fig. 6.
  • Fig. 7 shows the 1 H NMR spectrum of Pn * Zr(CI)(HC(N-4-Me-C 6 H 4 ) 2 ) recorded at 298 K in CD2CI2.
  • the molecular dimeric structure is depicted in Fig. 8. 1.3. Procedure for the synthesis of Pn * Zr(Q-2,6-Me-C6H3)(PhC(N l Pr) 2 )
  • Fig. 9 shows the 1 H NMR spectrum of Pn*Zr(0-2,6-Me-C 6 H 3 )(PhC(N'Pr) 2 ) recorded at 298 K in C 6 D 6 .
  • the molecular structure is depicted in Fig. 10.
  • Fig. 11 shows that all of the Example 1 compounds are potent catalysts for L-lactide polymerisation.
  • Fig. 12 shows that Pn*Zr(0-2,6-Me-C 6 H 3 )(PhC(N'Pr) 2 ) is a potent catalyst for e- caprolactone polymerisation.
  • Rh*T ⁇ (2,6-'RGq 6 H 3 N) 2 qH ⁇ OI was synthesised by reaction of 1 eq. [Pn*TiCl2]2 with 2 eq. K ⁇ (2,6-'PrC 6 H 3 N) 2 CH ⁇ in a NMR tube.
  • the 1 H NMR spectrum is shown in Fig. 15.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)

Abstract

Catalytic compounds suitable for use in the polymerisation of cyclic esters and/or cyclic amides are described. The catalytic compounds are based on Group IV metals bound to permethylpentalene and amidinate ligands.

Description

CATALYSTS
INTRODUCTION
[0001] The present invention relates to new catalytic compounds. More specifically, the present invention relates to catalytic compounds suitable for use in the polymerisation of cyclic esters and/or cyclic amides.
BACKGROUND OF THE INVENTION
[0002] Poly(lactic acids) (PLAs) have been studied intensively over the past few decades due to the promise they have shown as potential alternatives to petroleum-based polymers for uses a plastics, fibres and coatings. Moreover, since PLAs are both biodegradable and biocompatible, they are of equal value to the field of medicine, wherein their versatile physical properties make them suitable for in vivo applications (e.g. as media for controlled drug delivery devices).
[0003] Lactic acid forms PLA upon polycondensation. However, the fact that this reaction is in equilibrium, and the difficulties in completely removing water, makes it difficult to obtain PLAs of high molecular weight. With this in mind, ring opening polymerisation (ROP) of lactides is the most efficient route to PLAs with controlled molecular weights and narrow molecular weight distributions.
[0004] Metal complexes useful for initiating ring opening polymerisation of lactides are known.
[0005] Wenshan Ren et al, Inorganic Chemistry Communications, 30, (2013), 26-28 report that benzyl thorium metallocenes [q5-1 ,3-(Me3C)2C5H3]2 Th(CH2Ph)2 (1) and [q5-1 ,2,4-(Me3C)3C5H2]2 Th(CH2Ph)2 (2) can initiate the ring opening polymerisation of racemic-lactide (rac-LA) under mild conditions. Complete conversion of 500 equiv of lactide occurs within 5h at 40°C in dichloromethane at [rac-LA]=1.0 mol L 1 , and the molecular weight distribution is very narrow (ca.1.15) over the entire monomer-to-initiator range, indicating a single-site catalyst system.
[0006] Yalan Ning et al, Organometallics 2008, 27, 5632-5640 report four neutral zirconocene bis(ester enolate) and non-zirconocene bis(alkoxy) complexes employed for ring-opening polymerisations and chain transfer polymerisations of L-lactide ( -LA) and e-caprolactone (e-CL).
[0007] In spite of the above, due to the high value that industry places on such materials, there remains a need for catalysts/initiators capable of effectively polymerising cyclic esters (such as lactides and lactones) and cyclic amides.
The present invention was devised with the foregoing in mind. SUMMARY OF THE INVENTION
[0008] According to a first aspect of the present invention there is provided a compound having a structural formula according to formula (I) defined herein.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0009] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix, refers to any group having m to n carbon atoms.
[0010] The term“alkyl” as used herein refers to straight or branched chain alkyl moieties, typically having 1 , 2, 3, 4, 5 or 6 carbon atoms. This term includes reference to groups such as methyl, ethyl, propyl (n-propyl or isopropyl), butyl (n-butyl, sec-butyl or tert-butyl), pentyl, hexyl and the like. In particular, an alkyl may have 1 , 2, 3 or 4 carbon atoms.
[0011] The term“alkenyl” as used herein refers to straight or branched chain alkenyl moieties, typically having 1 , 2, 3, 4, 5 or 6 carbon atoms. The term includes reference to alkenyl moieties containing 1 , 2 or 3 carbon-carbon double bonds (C=C). This term includes reference to groups such as ethenyl (vinyl), propenyl (allyl), butenyl, pentenyl and hexenyl, as well as both the cis and trans isomers thereof.
[0012] The term“alkynyl” as used herein refers to straight or branched chain alkynyl moieties, typically having 1 , 2, 3, 4, 5 or 6 carbon atoms. The term includes reference to alkynyl moieties containing 1 , 2 or 3 carbon-carbon triple bonds (CºC). This term includes reference to groups such as ethynyl, propynyl, butynyl, pentynyl and hexynyl.
[0013] The term“haloalkyl” as used herein refers to alkyl groups being substituted with one or more halogens (e.g. F, Cl, Br or I). This term includes reference to groups such as 2-fluoropropyl, 3-chloropentyl, as well as perfluoroalkyl groups, such as perfluoromethyl.
[0014] The term“alkoxy” as used herein refers to -O-alkyl, wherein alkyl is straight or branched chain and comprises 1 , 2, 3, 4, 5 or 6 carbon atoms. In one class of embodiments, alkoxy has 1 , 2, 3 or 4 carbon atoms. This term includes reference to groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentoxy, hexoxy and the like.
[0015] The term "aryl" or“aromatic” as used herein means an aromatic ring system comprising 6, 7, 8, 9 or 10 ring carbon atoms. Aryl is often phenyl but may be a polycyclic ring system, having two or more rings, at least one of which is aromatic. This term includes reference to groups such as phenyl, naphthyl and the like. Unless otherwise specification, aryl groups may be substituted by one or more substituents. A particularly suitable aryl group is phenyl.
[0016] The term“aryloxy” as used herein refers to -O-aryl, wherein aryl has any of the definitions discussed herein. Also encompassed by this term are aryloxy groups in having an alkylene chain situated between the O and aryl groups.
[0017] The term "halogen" or“halo” as used herein refers to F, Cl, Br or I. In a particular, halogen may be F or Cl, of which Cl is more common.
[0018] The term“substituted” as used herein in reference to a moiety means that one or more, especially up to 5, more especially 1 , 2 or 3, of the hydrogen atoms in said moiety are replaced independently of each other by the corresponding number of the described substituents. The term“optionally substituted” as used herein means substituted or unsubstituted.
[0019] It will, of course, be understood that substituents are only at positions where they are chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without inappropriate effort whether a particular substitution is possible.
The terms“cyclic esters” and“cyclic amides” as used herein refer to heterocycles containing at least one ester or amide moiety. It will be understood that lactides, lactones and lactams are encompassed by these terms.
Compounds of the invention
[0020] As discussed above, the first aspect of the invention provides a compound having a structure according to formula (I) shown below:
Figure imgf000005_0001
wherein
X is selected from zirconium or hafnium; Y is selected from:
i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaRb, - NRaRb, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, nitro, -NRaRb, aryl, (1- 6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or
iii) a ligand having a structure according to formula A below:
Figure imgf000006_0001
A wherein
each Rx is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy, and
Ry is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy;
each R1 is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1- 3C)fluoroalkyl, aryl and aryloxy; and
R2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1- 3C)fluoroalkyl, aryl and aryloxy;
and wherein Ra and Rb are independently hydrogen or (1-4C)alkyl. [0021] Through intensive investigations, the inventors have developed new compounds that exhibit activity in catalysing the polymerisation of cyclic ester and cyclic amides. The new compounds, which contain a permethylpentalene (“Pn*”) ligands and an amidinate ligand, are particularly active in the polymerisation of lactides and lactones (e.g. e-caprolactone).
[0022] It will be appreciated that the compounds of formula (I) exist in a number of isomeric forms. For example, the exact nature of the bonding between metal X and the amidinate ligand may give rise to various isomeric forms, as illustrated below:
Figure imgf000007_0001
[0023] It will be appreciated that, depending on the nature of ligand Y, the compound of formula (I) may exist as a dimer. It will be understood that such dimeric forms of the compound of formula (I) are within the scope of the present invention. Dimeric forms of the compound of formula (I) may adopt the general structure:
Figure imgf000007_0002
[0024] Most suitably, X is zirconium.
[0025] In embodiments of first aspect of the invention, X may also be titanium.
[0026] In an embodiment, each R1 group is independently selected from (1-6C)alkyl, (2- 4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy.
[0027] Suitably, each R1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
[0028] More suitably, each R1 group is independently selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1- 6C)alkoxy, aryl and aryloxy.
[0029] Even more suitably, each R1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
[0030] Yet more suitably, each R1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with 1-3 groups selected from halo, (1-4C)alkyl and (1- 2C)alkoxy.
[0031] In a particularly suitable embodiment, each R1 group is independently selected from methyl, ethyl, isopropyl and tertbutyl, or each R1 group is independently a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl.
[0032] Both R1 groups are suitably identical to one another.
[0033] In an embodiment, R2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
[0034] Suitably, R2 is selected from hydrogen, (1-6C)alkyl, -N'Pr'Pr and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, (1- 3C)fluoroalkyl, aryl and aryloxy.
[0035] More suitably, R2 is selected from hydrogen, (1-4C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, aryl and aryloxy.
[0036] Even more suitably, R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
[0037] Yet more suitably, R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl. [0038] In a particularly suitable embodiment, R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1- 4C)alkyl.
[0039] In an embodiment, Ra and Rb are independently selected from methyl, ethyl, iso-propyl and tert-butyl.
[0040] Suitably, Ra and Rb are independently selected from methyl, ethyl and iso-propyl.
[0041] More suitably, Ra and Rb are identical.
[0042] When taken in combination with the group -N-C(R2)H-N-, the groups R1 and R2 form an amidinate ligand -(R1)N-C(R2)H-N(R1)-. Exemplary amidinate ligands useful in the context of the present invention are as follows:
Figure imgf000009_0001
[0043] In an embodiment, Y is i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaRb, -NRaRb, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1- 4C)alkyl, nitro, -NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or iii) a ligand having a structure according to formula A, wherein each Rx has any of the definitions discussed hereinbefore in relation to R1, and Ry has any of the definitions discussed hereinbefore in relation to R2.
[0044] Suitably, Y is
i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaR , -NRaR , aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1- 4C)alkyl, nitro, -NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or iii) a ligand having a structure according to formula A, wherein both R1 groups are identical, each Rx is identical to R1 , and Ry is identical to R2.
[0045] More suitably, Y is
i) halo, or ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, -NRaRb, aryl, (1- 6C)alkoxy, -C(0)NRaR , and Si[(1-4C)alkyl]3.
[0046] Even more suitably, Y is
i) halo, or ii) (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, aryl and (1-6C)alkoxy.
[0047] Yet more suitably, Y is
i) halo, or ii) (1-4C)alkyl, (1-4C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
[0048] Yet even more suitably, Y is
i) chloro or bromo, or ii) (1-4C)alkoxy, phenyl and phenoxy, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
[0049] In a particularly suitable embodiment, Y is
i) chloro, or ii) (1-4C)alkoxy, phenyl and phenoxy, any of which is optionally substituted with 1-3 groups selected from halo and (1-4C)alkyl.
[0050] In another particularly suitable embodiment, Y is
i) chloro, or ii) (1-4C)alkoxy (e.g. f-butoxy) or a phenoxy group that is optionally substituted (e.g. at the ortho position) with 1 or 2 (1-4C)alkyl groups (e.g. methyl or isopropyl).
[0051] In an embodiment, the compound of formula (I) has a structure according to formula (la) shown below:
Figure imgf000011_0001
wherein
X, Y and R2 have any of the definitions discussed hereinbefore in respect of formula (I); each R3 is independently selected from (1-4C)alkyl and (1-3C)fluoroalkyl; and each n is independently 0,1 , 2 or 3. [0052] Suitably, the compound of formula (I) has a structure according to formula (la), wherein
X, Y and R2 have any of the definitions discussed hereinbefore in respect of formula (I);
each R3 is independently an ortho or para substituent selected from (1-4C)alkyl and (1- 3C)fluoroalkyl; and
each n is independently 0, 1 , 2 or 3.
[0053] More suitably, the compound of formula (I) has a structure according to formula (la), wherein
X is zirconium;
R2 is selected from hydrogen, (1-6C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy
Y is: i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaRb, -NRaRb, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1- 4C)alkyl, nitro, -NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or iii) an amidinate ligand identical to that depicted in formula (la) (i.e. that comprising groups R1 and R2); each R3 is independently an ortho or para substituent selected from (1-4C)alkyl and (1- 3C)fluoroalkyl; and
each n is independently 0, 1 , 2 or 3.
[0054] Even more suitably, the compound of formula (I) has a structure according to formula (la), wherein
X is zirconium;
R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl;
Y is: i) halo, or ii) (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, aryl and (1-6C)alkoxy; each R3 is independently an ortho or para substituent selected from (1-4C)alkyl and (1- 3C)fluoroalkyl; and
each n is independently 0, 1 , 2 or 3.
[0055] Yet more suitably, the compound of formula (I) has a structure according to formula (la), wherein
X is zirconium;
R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl;
Y is: i) chloro, or ii) (1-4C)alkoxy or a phenoxy group that is optionally substituted with 1 or 2 (1-4C)alkyl groups; each R3 is independently an ortho or para substituent selected from methyl, iso-propyl and trifluoromethyl; and
each n is independently 0, 1 , 2 or 3.
[0056] In an embodiment, the compound of formula (I) has a structure according to formula (lb) shown below:
Figure imgf000013_0001
wherein
X, Y and R2 have any of the definitions discussed hereinbefore in respect of formula (I).
[0057] Suitably, the compound of formula (I) has a structure according to formula (lb), wherein X is zirconium;
R2 is selected from hydrogen, (1-6C)alkyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, (1- 3C)fluoroalkyl, aryl and aryloxy;
Y is: i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaRb, -NRaRb, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1- 4C)alkyl, nitro, -NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or iii) an amidinate ligand identical to that depicted in formula (la) (i.e. that comprising groups R1 and R2).
[0058] More suitably, the compound of formula (I) has a structure according to formula (lb), wherein
X is zirconium;
R2 is selected from hydrogen, (1-4C)alkyl, -N'PHPr and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy and (1- 3C)fluoroalkyl;
Y is: i) halo, or ii) (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, aryl and (1-6C)alkoxy.
[0059] Even more suitably, the compound of formula (I) has a structure according to formula (lb), wherein
X is zirconium;
R2 is selected from hydrogen, (1-4C)alkyl, -N'PHPr and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy and trifluoromethyl;
Y is: i) chloro, or ii) (1-4C)alkoxy or a phenoxy group that is optionally substituted with 1 or 2 (1-4C)alkyl groups.
[0060] In an embodiment, the compound of formula (I) has a structure according to formula (lc) shown below:
Figure imgf000015_0001
wherein
X, R1 and R2 have any of the definitions discussed hereinbefore in respect of formula (I).
[0061] In an embodiment, the compound of formula (I) has a structure according to formula (lc) wherein
X is zirconium;
each R1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy; and
R2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
[0062] In an embodiment, the compound of formula (I) has a structure according to formula (lc) wherein
X is zirconium;
each R1 group is independently selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, (1- 3C)haloalkyl, aryl and aryloxy; and R2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -N'Pr'Pr and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
[0063] In an embodiment, the compound of formula (I) has a structure according to formula (lc) wherein
X is zirconium;
each R1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy; and
R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
[0064] In an embodiment, the compound of formula (I) has a structure according to formula (lc) wherein
X is zirconium;
R1 group is selected from methyl, ethyl, isopropyl and tertbutyl, or R1 group is a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl; and
R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
[0065] In an embodiment, the compound of formula (I) has a structure according to formula (Id) shown below:
Figure imgf000016_0001
wherein X, R1 and R2 have any of the definitions discussed hereinbefore in respect of formula (I); and
R4 is selected from (1-4C)alkyl and aryl, either or which is optionally substituted with one or more substituents selected from (1-4C)alkyl and (1-3C)fluoroalkyl.
[0066] In an embodiment, the compound of formula (I) has a structure according to formula (Id) wherein
X is zirconium;
each R1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy;
R2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy; and
R4 is selected from (1-4C)alkyl and phenyl, either or which is optionally substituted with one or more substituents selected from (1-4C)alkyl and (1-3C)fluoroalkyl.
[0067] In an embodiment, the compound of formula (I) has a structure according to formula (Id) wherein
X is zirconium;
each R1 group is independently selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, (1- 3C)haloalkyl, aryl and aryloxy; and
R2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -N'Pr'Pr and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
[0068] In an embodiment, the compound of formula (I) has a structure according to formula (Id) wherein
X is zirconium;
each R1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy;
R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy; and R4 is selected from methyl, iso-propyl, tert-butyl and phenyl, either or which is optionally substituted with one or more substituents selected from methyl, iso-propyl, tert-butyl and trifluoromethyl.
[0069] In an embodiment, the compound of formula (I) has a structure according to formula (Id) wherein
X is zirconium;
R1 group is selected from methyl, ethyl, isopropyl and tertbutyl, or R1 group is a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl;
R2 is selected from hydrogen, (1-4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl; and
R4 is selected from tert-butyl, 2,6-dimethyl phenyl and 2,6-diisopropyl phenyl.
[0070] In an embodiment, the compound of formula (I) has any of the following structures:
Figure imgf000019_0001
[0071] In an embodiment, the compound of formula (I) has any of the following structures:
Figure imgf000020_0001
[0072] Suitably, the compound of formula (I) has any of the following structures:
Figure imgf000021_0001
[0073] In an embodiment, the compound of formula (I) has any of the following structures:
Figure imgf000021_0002
[0074] In an embodiment, the compound of formula (I) is immobilised on a solid support material. Supporting the compound on such a solid support allows the resulting material to be used in slurry phase (as opposed to solution phase) catalysis. Suitable solid support materials will be familiar to one of ordinary skill in the art. The compound of formula (I) may be supported directly or indirectly (e.g. by a linking moiety) on the solid support material. It will be understood that the compound of formula (I) may undergo one or more minor structure modifications (e.g. loss of the group Y) as a consequence of having been immobilised on a solid support material. Such minor structural modifications are within the scope of the invention. Synthesis
[0075] The compounds of formula (I) may be synthesised by any suitable process known in the art. Particular examples of processes for the preparation of the compounds are set out in the accompanying examples.
[0076] Suitably, the compounds of formula (I) are prepared according to a process comprising the steps of:
a) reacting a compound of formula (II) shown below:
Figure imgf000022_0001
wherein X is as defined in formula (I), M is a metal (such as Li, Na or K) and Q is halo (e.g. chloro);
with a compound of formula (III) shown below:
Figure imgf000022_0002
wherein R1 and R2 are as defined in formula (I) and M+ is a metal cation (such as Li+, Na+ or K+); and optionally thereafter
b) reacting the resulting product with a compound of formula (IV) shown below:
M(Y)
(IV)
wherein Y is as defined in formula (I) and M is a metal (such as Li, Na or K).
[0077] If a compound of formula (I) is required in which Y is other than halo, then step b) is typically implemented.
[0078] Suitably, M is Li in step a).
[0079] Any suitable solvent may be used for steps a) and b) of the process defined above. A particularly suitable solvent may be, for example, diethyl ether, toluene, THF, dichloromethane, chloroform, hexane DMF, benzene etc.
[0080] Within step a), the compound of formula (III) is typically added dropwise to the compound of formula (II) in order to prevent double ligand substitution (unless this is desired).
[0081] A person of skill in the art will be able to select suitable reaction conditions (e.g. temperature, pressures, reaction times, agitation etc.) for such a synthesis.
[0082] The following numbered statements 1 to 33 are not claims, but instead serve to define particular aspects and embodiments of the claimed invention:
1. A compound having a structure according to formula I shown below:
Figure imgf000023_0001
(l) wherein
X is selected from zirconium, hafnium and titanium;
Y is selected from:
i) halo, hydrogen, a phosphonate, sulfonate or borate anion, ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaRb, - NRaRb, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, nitro, -NRaRb, aryl, (1- 6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or
iii) a ligand having a structure according to formula A below:
Figure imgf000024_0001
A wherein
each Rx is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy, and
Ry is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy;
each R1 is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1- 3C)fluoroalkyl, aryl and aryloxy; and R2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1- 3C)fluoroalkyl, aryl and aryloxy;
and wherein Ra and Rb are independently hydrogen or (1-4C)alkyl. The compound of statement 1 , wherein X is zirconium. The compound of statement 1 or 2, wherein each R1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy. The compound of any one of statements 1 , 2 or 3, wherein each R1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy. The compound of any preceding statement, wherein each R1 group is independently selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy. The compound of any preceding statement, wherein each R1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy. The compound of any preceding statement, wherein each R1 group is independently selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with 1-3 groups selected from halo, (1-4C)alkyl and (1-2C)alkoxy. The compound of any preceding statement, wherein each R1 group is independently selected from methyl, ethyl, isopropyl and tertbutyl, or each R1 group is independently a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl. The compound of any preceding statement, wherein both R1 groups are identical The compound of any preceding statement, wherein R2 is selected from hydrogen, (1- 6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy. The compound of any preceding statement, wherein R2 is selected from hydrogen, (1- 6C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy. The compound of any preceding statement, wherein R2 is selected from hydrogen, (1- 4C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, aryl and aryloxy. The compound of any preceding statement, wherein R2 is selected from hydrogen, (1- 4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy. The compound of any preceding statement, wherein R2 is selected from hydrogen, (1- 4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl. The compound of any preceding statement, wherein R2 is selected from hydrogen, (1- 4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl. The compound of any preceding statement, wherein the group -(R1)N-CH(R2)-N(R1)- is an amidinate ligand having any one of the following structures:
Figure imgf000027_0001
The compound of any preceding statement, wherein Y is
i) halo, hydrogen, a phosphonate, sulfonate or borate anion,
ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaRb, -NRaRb, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, nitro, -NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or iii) a ligand having a structure according to formula A, wherein each Rx has any of the definitions appearing in any preceding statement in relation to R1, and Ry has any of the definitions appearing in any preceding statement in relation to R2. The compound of any preceding statement, wherein Y is
i) halo, hydrogen, a phosphonate, sulfonate or borate anion,
ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaR , -NRaR , aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, nitro, -NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or iii) a ligand having a structure according to formula A, wherein each Rx is identical to R1 , and Ry is identical to R2. The compound of any preceding statement, wherein Y is
i) halo, or
ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, - NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3. The compound of any preceding statement, wherein Y is
i) halo, or
ii) (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, aryl and (1-6C)alkoxy. The compound of any preceding statement, wherein Y is
i) halo, or
ii) (1-4C)alkyl, (1-4C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl. The compound of any preceding statement, wherein Y is
i) chloro or bromo, or
ii) (1-4C)alkoxy, phenyl and phenoxy, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl. The compound of any preceding statement, wherein Y is
i) chloro, or
ii) (1-4C)alkoxy, phenyl and phenoxy, any of which is optionally substituted with 1-3 groups selected from halo and (1-4C)alkyl. The compound of any preceding statement, wherein Y is
i) chloro, or
ii) (1-4C)alkoxy or a phenoxy group that is optionally substituted with 1 or 2 (1-4C)alkyl groups. The compound of any preceding statement, wherein the compound of formula (I) has a structure according to formula (la) shown below:
Figure imgf000029_0001
wherein
X, Y and R2 are as defined in any preceding statement; each R3 is independently selected from (1-4C)alkyl and (1-3C)fluoroalkyl; and each n is independently 0, 1 , 2 or 3. The compound of any one of statements 1 to 24, wherein the compound of formula (I) has a structure according to formula (lb) shown below:
Figure imgf000029_0002
wherein
X, Y and R2 are as defined in any preceding statement; The compound of any one of statements 1 to 24, wherein the compound of formula (I) has a structure according to formula (lc) shown below:
Figure imgf000030_0001
wherein
X, R1 and R2 are as defined in any preceding statement. The compound of any one of statements 1 to 24, wherein the compound of formula (I) has a structure according to formula (Id) shown below:
Figure imgf000030_0002
wherein
X, R1 and R2 are as defined in any preceding statement; and
R4 is selected from (1-4C)alkyl and aryl, either or which is optionally substituted with one or more substituents selected from (1-4C)alkyl and (1-3C)fluoroalkyl. The compound of statement 1 , wherein the compound has any of the following structures:
Figure imgf000031_0001
The compound of statement 1, wherein the compound has any of the following structures:
Figure imgf000032_0001
31. The compound of statement 1, wherein the compound has any of the following structures:
WO 2019/166782 PCT/GB2019/050489
31
Figure imgf000033_0001
32. The compound of statement 1 , wherein the compound has any of the following
structures:
Figure imgf000033_0002
33. The compound of any preceding statement, wherein the compound of formula (I) is
immobilised on a solid support material.
EXAMPLES
[0083] Examples of the invention will now be described, for the purpose of illustration only, with reference to the accompanying figures, in which:
Fig. 1 shows the 1H NMR spectrum of Pn*Zr(CI)(HC(N-2,6-'Pr-C6H3)2) recorded at 298 K in CD2CI2. *denotes NMR solvent residue.
Fig. 2 shows the molecular structure of Pn*Zr(CI)(HC(N-2,6-'Pr-C6H3)2), shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity. Fig. 3 shows the 1 H NMR spectrum of Pn*Zr(CI)(MeC(N'Pr)2) recorded at 298 K in Obϋd. *denotes NMR solvent residue.
Fig. 4 shows the molecular structure of dimeric [Pn*Zr(CI)(MeC(N'Pr)2)]2, shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity.
Fig. 5 shows the 1 H NMR spectrum of Pn*Zr(CI)(PhC(N'Pr)2) recorded at 298 K in Obϋd. *denotes NMR solvent residue and residual THF.
Fig. 6 shows the molecular structure of Pn*Zr(CI)(PhC(N'Pr)2), shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity. An additional symmetry inequivalent molecule composes the asymmetric unit and is also omitted for clarity.
Fig. 7 shows the 1 H NMR spectrum of Pn*Zr(CI)(HC(N-4-Me-C6H4)2) recorded at 298 K in CD2CI2. *denotes NMR solvent residue and residual hexane.
Fig. 8 shows the molecular structure of dimeric [Pn*Zr(CI)(HC(N-4-Me-C6H4)2)]2, shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity.
Fig. 9 shows the 1 H NMR spectrum of Pn*Zr(0-2,6-Me-C6H3)(PhC(N'Pr)2) recorded at 298 K in Odϋd. *denotes NMR solvent residue.
Fig. 10 shows the molecular structure of Pn*Zr(0-2,6-Me-C6H3)(PhC(N'Pr)2), shown with thermal ellipsoids at 50% probability and hydrogen atoms removed for clarity. An additional symmetry inequivalent molecule composes the asymmetric unit and is also omitted for clarity.
Fig. 11 is a plot showing conversion of L-lactide to Polylactide as a function of time using the compounds of Example 1. Reactions catalysed by the series of permethylpentalene zirconium catalysts. Polymerisations were performed in a 0.5M L-lactide solution in Obϋd at 80 °C with 2 mol% [Zr]
Fig. 12 is a plot showing concentration of e-caprolactone monomer as a function of polymerisation time using Pn*Zr(0-2,6-Me-C6H3)(PhC(N'Pr)2), with the reaction following a zero order rate law. Polymerisations were performed in a 0.5M e-caprolactone solution in Obϋd at room temperature with 2 mol% Pn*Zr(0-2,6-Me-C6H3)(PhC(N'Pr)2).
Fig. 13 shows the 1 H NMR spectrum of Pn*Zr{('PrN)2C(4-OMe-C6H4)}CI recorded at 298K in Odϋd. *denotes NMR solvent residue and # denotes residual thf.
Fig. 14 shows the 1 H NMR spectrum of Pn*Zr{('PrN)2C(4-CF3-C6H4)}CI recorded at 298K in Obϋd. *denotes NMR solvent residue and # denotes residual thf.
Fig. 15 shows the 1 H NMR spectrum of Pn*Ti{(2,6-'PrC6H3N)2CH}CI recorded at 298K in Obϋd. *denotes NMR solvent residue. Fig. 16 shows the 1H NMR spectrum of Pn*Ti{('PrN)2C(C6H5)}CI recorded at 298K in CeD6. *denotes NMR solvent residue and # denotes residual pentane.
Figure imgf000035_0001
Example 1 - Synthesis of compounds
1.1. General procedure for the synthesis of Pn*Zr(CI)L (L = and
Figure imgf000035_0002
PhC(N'Pr)?
[0084] [Pn*ZrCl2]2LiCI THFx (0.114 mmol) and a metal salt of the desired ligand (M-L*, 0.229 mmol) were combined as solids in a Schlenk tube and toluene (3 ml_) was added at room temperature. When L = MeC(N'Pr)2 or PhC(N'Pr)2 solutions were stirred for 2 hours at room temperature and when L = HC(N-2,6-'Pr-C6H3)2 the solution was stirred at 60 °C for 15 h. In all cases all volatiles were removed in vacuo and the residues extracted into toluene and filtered through celite. Toluene was removed in vacuo and the products extracted into hexane and filtered to remove remaining LiCI. Crystals of each product were obtained by cooling concentrated hexane solutions to -30 °C. Crystals were isolated by filtration. [*Lithium salts were used for MeC(N'Pr)2 and PhC(N'Pr)2 whilst a potassium salt of HC(N-2,6-'Pr-C6H3)2 was used.]
[0085] Fig. 1 shows the 1H NMR spectrum of Pn*Zr(CI)(HC(N-2,6-'Pr-C6H3)2) recorded at 298 K in CD2CI2. The molecular structure is depicted in Fig. 2.
[0086] Fig. 3 shows the 1H NMR spectrum of Pn*Zr(CI)(MeC(N'Pr)2) recorded at 298 K in CeD6. The molecular dimeric structure is depicted in Fig. 4.
[0087] Fig. 5 shows the 1H NMR spectrum of Pn*Zr(CI)(PhC(N'Pr)2) recorded at 298 K in CeD6. The molecular structure is depicted in Fig. 6.
1.2. Procedure for the synthesis of Pn*Zr(CI)(HC(N-4-Me-C6H4)2)
[0088] [Pn*ZrCI2]2LiCI THFx (0.114 mmol) and K[HC(N-4-Me-C6H4)2] (0.229 mmol) were added to separate Schlenk tubes and each dissolved in toluene (2 ml_). The solution of the ligand was then added dropwise to that of [Pn*ZrCl2]2LiCI THFx at -20 °C to prevent double ligand substitution. The reaction was returned to room temperature and stirred for 1 h after which all volatiles volatiles were removed in vacuo. The residue was extracted into toluene and filtered (multiple times if required) to remove LiCI. Toluene was removed in vacuo and hexane added to precipitate the product.
[0089] Fig. 7 shows the 1H NMR spectrum of Pn*Zr(CI)(HC(N-4-Me-C6H4)2) recorded at 298 K in CD2CI2. The molecular dimeric structure is depicted in Fig. 8. 1.3. Procedure for the synthesis of Pn*Zr(Q-2,6-Me-C6H3)(PhC(NlPr)2)
[0090] [Pn*ZrCI2]2LiCI THFx (0.1 14 mmol) and K[PhC(N'Pr)2] (0.229 mmol) were combined in a schlenk tube and toluene (3 mL) was added and the solution stirred for 1 h. The reaction mixture was then transferred to a flask containing K[0-2,6-Me-C6H3] (0.229 mmol) and stirred for a further 1 hour. All volatiles were removed in vacuo and the residues extracted into toluene and filtered through celite. Toluene was removed in vacuo and the product was extracted into hexane and filtered to remove remaining LiCI. Crystals were obtained by cooling concentrated hexane solutions to -30 °C. Crystals were isolated by filtration.
[0091] Fig. 9 shows the 1 H NMR spectrum of Pn*Zr(0-2,6-Me-C6H3)(PhC(N'Pr)2) recorded at 298 K in C6D6. The molecular structure is depicted in Fig. 10.
Example 2 - Polymerisation studies
2.1. L-lactide polymerisation
[0092] The ability of the compounds of Example 1 to catalyse the polymerisation of L-lactide was assessed. Polymerisation experiments were conducted in a 0.5M L-lactide solution in Obϋd at 80 °C with 2 mol% [Zr]
[0093] Fig. 11 shows that all of the Example 1 compounds are potent catalysts for L-lactide polymerisation.
2.2. e-caprolactone polymerisation
[0094] The ability of Pn*Zr(0-2,6-Me-C6H3)(PhC(N'Pr)2) to catalyse the polymerisation of e- caprolactone was assessed. Polymerisation experiments were conducted in a 0.5M e- caprolactone solution in CeD6 at room temperature with 2 mol% Pn*Zr(0-2,6-Me- C6H3)(PhC(N'Pr)2).
[0095] Fig. 12 shows that Pn*Zr(0-2,6-Me-C6H3)(PhC(N'Pr)2) is a potent catalyst for e- caprolactone polymerisation.
Figure imgf000037_0001
Example 3 - Synthesis of further compounds
3.1. Procedure for the synthesis of Pn*Zr(('PrN)2C(4-R-C6H4))CI (R=OMe, CF3)
[0096] Pn*Zr{('PrN)2C(4-R-C6H4)}CI (R=OMe, CF3) was prepared by the reaction of 1 eq. [Pn*ZrCl2]2 LiCl thf2 with 2 eq. (l\rPr)2C(PhR) (R = OMe, CF3) in a NMR tube. The 1 H NMR spectra are shown in Figs. 13 and 14.
3.2. Procedure for the synthesis of Pn*Ti{(2,6-'PrC6H3N)2CH)CI
[0097] Rh*Tί{(2,6-'RGq6H3N)2qH}OI was synthesised by reaction of 1 eq. [Pn*TiCl2]2 with 2 eq. K{(2,6-'PrC6H3N)2CH}in a NMR tube. The 1 H NMR spectrum is shown in Fig. 15.
3.3. Procedure for the synthesis of )CI
Figure imgf000037_0002
[0098] Pn*Ti{('PrN)2C(C6H5)}CI was synthesised by reaction of 1 eq. [Pn*TiCl2]2 with 2 eq. Li{( 'PrN)2C(C6H5)}in a NMR tube. The 1 H NMR spectrum is shown in Fig. 16.
While specific embodiments of the invention have been described herein for the purpose of reference and illustration, various modifications will be apparent to a person skilled in the art without departing from the scope of the invention as defined by the appended claims.

Claims

1. A compound having a structure according to formula I shown below:
Figure imgf000038_0001
wherein
X is selected from zirconium, hafnium and titanium;
Y is selected from:
i) halo, hydrogen, a phosphonate, sulfonate or borate anion,
ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaRb, - NRaRb, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, nitro, -NRaRb, aryl, (1- 6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or
iii) a ligand having a structure according to formula A below:
Figure imgf000038_0002
A wherein
each Rx is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy, and
Ry is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy;
each R1 is independently selected from (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1- 3C)fluoroalkyl, aryl and aryloxy; and
R2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1- 3C)fluoroalkyl, aryl and aryloxy;
and wherein Ra and Rb are independently hydrogen or (1-4C)alkyl.
2. The compound of claim 1 , wherein X is zirconium.
3. The compound of claim 1 or 2, wherein each R1 group is independently selected from (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, - NRaRb, (1-6C)alkoxy, -C(0)NRaRb, (1-3C)fluoroalkyl, aryl and aryloxy.
4. The compound of any preceding claim, wherein each R1 group is independently
selected from (1-6C)alkyl and aryl, either of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, aryl and aryloxy.
5. The compound of any preceding claim, wherein each R1 group is independently
selected from (1-4C)alkyl and phenyl, either of which is optionally substituted with 1-3 groups selected from halo, (1-4C)alkyl and (1-2C)alkoxy.
6. The compound of any preceding claim, wherein each R1 group is independently
selected from methyl, ethyl, isopropyl and tertbutyl, or each R1 group is independently a phenyl group that is optionally substituted with 1-3 groups selected from methyl, ethyl, isopropyl and tertbutyl.
7. The compound of any preceding claim, wherein both R1 groups are identical
8. The compound of any preceding claim, wherein R2 is selected from hydrogen, (1- 6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -NRaRb and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-6C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, (1-6C)alkoxy, (1-3C)fluoroalkyl, aryl and aryloxy.
9. The compound of any preceding claim, wherein R2 is selected from hydrogen, (1- 4C)alkyl and aryl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, aryl and aryloxy.
10. The compound of any preceding claim, wherein R2 is selected from hydrogen, (1- 4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, (1-2C)alkoxy, phenyl and phenoxy.
11. The compound of any preceding claim, wherein R2 is selected from hydrogen, (1- 4C)alkyl and phenyl, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
12. The compound of any preceding claim, wherein Y is
i) halo, hydrogen, a phosphonate, sulfonate or borate anion,
ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, -C(0)NRaRb, -NRaRb, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, nitro, -NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3, or iii) a ligand having a structure according to formula A, wherein each Rx has any of the definitions appearing in any preceding claim in relation to R1, and Ry has any of the definitions appearing in any preceding claim in relation to R2.
13. The compound of any preceding claim, wherein Y is
i) halo, or
ii) (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo, (1-4C)alkyl, - NRaRb, aryl, (1-6C)alkoxy, -C(0)NRaRb, and Si[(1-4C)alkyl]3.
14. The compound of any preceding claim, wherein Y is
i) halo, or ii) (1-4C)alkyl, (1-4C)alkoxy, aryl and aryloxy, any of which is optionally substituted with one or more groups selected from halo and (1-4C)alkyl.
15. The compound of any preceding claim, wherein Y is
i) chloro, or
ii) (1-4C)alkoxy or a phenoxy group that is optionally substituted with 1 or 2 (1-4C)alkyl groups.
16. The compound of claim 1 , wherein the compound has any of the following structures:
Figure imgf000041_0001
17. The compound of claim 1 , wherein the compound has any of the following structures:
Figure imgf000042_0001
18. The compound of claim 1 , wherein the compound has any of the following structures:
Figure imgf000043_0001
19. The compound of claim 1 , wherein the compound has any of the following structures:
Figure imgf000043_0002
20. The compound of any preceding claim, wherein the compound of formula (I) is immobilised on a solid support material.
PCT/GB2019/050489 2018-02-27 2019-02-22 Catalysts WO2019166782A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1803208.6 2018-02-27
GBGB1803208.6A GB201803208D0 (en) 2018-02-27 2018-02-27 Catalysts

Publications (1)

Publication Number Publication Date
WO2019166782A1 true WO2019166782A1 (en) 2019-09-06

Family

ID=61903217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2019/050489 WO2019166782A1 (en) 2018-02-27 2019-02-22 Catalysts

Country Status (2)

Country Link
GB (1) GB201803208D0 (en)
WO (1) WO2019166782A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155214A2 (en) * 2014-04-09 2015-10-15 Scg Chemicals Co., Ltd. Lactide polymerisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155214A2 (en) * 2014-04-09 2015-10-15 Scg Chemicals Co., Ltd. Lactide polymerisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUNCAN A. X. FRASER ET AL: "Titanium and Zirconium Permethylpentalene Complexes, Pn*MCp R X, as Ethylene Polymerization Catalysts", ORGANOMETALLICS, vol. 35, no. 16, 22 August 2016 (2016-08-22), US, pages 2664 - 2674, XP055325330, ISSN: 0276-7333, DOI: 10.1021/acs.organomet.6b00417 *

Also Published As

Publication number Publication date
GB201803208D0 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
Alaaeddine et al. Aluminum and yttrium complexes of an unsymmetrical mixed fluorous alkoxy/phenoxy-diimino ligand: synthesis, structure, and ring-opening polymerization catalysis
Schwarz et al. Sulfonamide-supported aluminum catalysts for the ring-opening polymerization of rac-lactide
Kan et al. Aluminum methyl, alkoxide and α-alkoxy ester complexes supported by 6, 6′-dimethylbiphenyl-bridged salen ligands: synthesis, characterization and catalysis for rac-lactide polymerization
Xie et al. Phosphinimino-amino magnesium complexes: synthesis and catalysis of heteroselective ROP of rac-lactide
Dijkstra et al. Single site catalysts for stereoselective ring-opening polymerization of lactides
Bouyahyi et al. Aluminum complexes of fluorinated β-diketonate ligands: syntheses, structures, intramolecular reduction, and use in ring-opening polymerization of lactide
Peckermann et al. Indium complexes supported by 1, ω-dithiaalkanediyl-bridged bis (phenolato) ligands: synthesis, structure, and controlled ring-opening polymerization of L-lactide
Schwarz et al. Sulfonamide-supported group 4 catalysts for the ring-opening polymerization of ε-caprolactone and rac-lactide
Bakewell et al. Yttrium phosphasalen initiators for rac-lactide polymerization
Wang et al. Zinc complexes supported by multidentate aminophenolate ligands: synthesis, structure and catalysis in ring-opening polymerization of rac-lactide
Huang et al. Ring-opening polymerization of rac-lactide and α-methyltrimethylene carbonate catalyzed by magnesium and zinc complexes derived from binaphthyl-based iminophenolate ligands
Shi et al. Bimetallic aluminum complexes supported by bis (salicylaldimine) ligand: Synthesis, characterization and ring-opening polymerization of lactide
EP3359585B1 (en) Use of compounds in polymerisation reactions
Bai et al. β-Pyridylenolate zinc catalysts for the ring-opening homo-and copolymerization of ε-caprolactone and lactides
Forder et al. Synthesis and characterisation of aluminium (III) imine bis (phenolate) complexes with application for the polymerisation of rac-LA
Oishi et al. Ring-Opening Polymerization of ε-Caprolactone Initiated by Multinuclear Aluminum Methanetris (aryloxido) Complexes
Jiang et al. Phenoxy-imine/-amide aluminum complexes with pendant or coordinated pyridine moieties: Solvent effects on structural type and catalytic capability for the ROP of cyclic esters
Gao et al. Stereoselective ring-opening polymerization of rac-lactides catalyzed by titanium complexes containing N, N-bidentate phenanthrene derivatives
JP2014505027A (en) Zirconium complexes based on N-heterocyclic carbenes for use in ring-opening polymerization of lactones
WO2019166782A1 (en) Catalysts
CN109749072B (en) Method for catalyzing lactide polymerization by dinuclear amine imine magnesium complex
CN109734880B (en) Method for catalyzing lactide polymerization by using binuclear chiral amine imine magnesium complex
WO2019166783A1 (en) Polymerisation of cyclic esters and cyclic amides
CN102827200A (en) Nitrogenous bisphenol oxygroup ligand titanium compound and preparation method thereof and application thereof
JP2020532583A (en) Suitable catalysts for ring-opening polymerization of cyclic esters and cyclic amides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19708637

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19708637

Country of ref document: EP

Kind code of ref document: A1